PO-508 A novel predictor for stratifying pancreatic cancer patients to DNA damage checkpoint inhibitors

Abstract

Introduction Checkpoint Kinase 1 (CHK1) plays a central role in the DNA damage response, particularly in cell cycle arrest and DNA damage repair. CHK1 inhibitors (CHK1i) were originally developed as chemo-potentiators in cancers with p53 mutations. Several CHK1i have been in clinical evaluation for many years with varying success rates. We propose that stratification of patients using predictive biomarkers of response and optimal scheduling of treatment are essential to obtain the best responses in the clinic. In vitro pharmaco-trancriptomic analysis revealed a novel predictor of CHK1i responsiveness. High expression of this predictor had previously been associated with poor survival in panc..